Two signaling targets along the MAPK pathway in treating melanoma are mutated serine/threonine-protein kinase B-Raf (BRAF) [11,12] and mitogen-activated protein kinase kinase (MEK) [13]. The gene discussed is WNK2; the disease is melanoma.